RAPAFLO

This brand name is authorized in Canada, United States

Active ingredients

The drug RAPAFLO contains one active pharmaceutical ingredient (API):

1 Silodosin UNII CUZ39LUY82 - SILODOSIN

Silodosin is highly selective for α1A-adrenoreceptors that are primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these α1A-adrenoreceptors causes smooth muscle in these tissues to relax, thus decreasing bladder outlet resistance, without affecting detrusor smooth muscle contractility. Read about Silodosin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RAPAFLO Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04CA04	Silodosin	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02361663, 02361671
Country: US	FDA, National Drug Code	Identifier(s): 0023-6142, 0023-6147, 52544-151